June 2021 Activities Report and Appendix 4C

HIGHLIGHTS:

- **Strong cash balance of $16.1m driving development of multiple cancer programs**
- **Agreement with Peter MacCallum Cancer Centre, led by Prof. Phil Darcy, to accelerate the development of OmniCAR and its three internal CAR-T programs**
- **Cell Therapy Enhancements programs seeking to overcome significant challenges associated with cell manufacturing consoliated into a joint program at Peter Mac**
- **PTX-200 AML Phase 1b completed second cohort at 35 mg/m^2 dose level and has progressed to next dose level at 45 mg/m^2**
- **Post reporting period, PTX-100 Phase 1b basket trial successfully completed and will now progress into an expansion cohort study led again by Prof Miles Prince at Epworth Hospital in Australia**
- **Join an investor briefing this morning at 11am Click here to book your spot.**

MELBOURNE Australia, 30 July 2021 – Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company developing personalised medicine approaches to cancer, today reported its June 2021 quarter results and operating highlights.

The Company remains in a strong financial position and its multiple cancer programs continue to make timely progress towards a number of value creating milestones.

Financial update

Prescient ended the quarter with a cash balance of $16.1 million. Costs for the quarter included the ongoing clinical studies of PTX-100 and PTX-200; research and development of OmniCAR and Cell Therapy Enhancements.

Cash outflows for the quarter were $1.14 million, with $0.28 million invested in research and development activities in Australia and the United States. Payments during the period to related parties of the entity and associates, which are outlined in Section 6.1 of the accompanying Appendix 4C were $82,000. These payments were largely related to non-executive director fees and salary, superannuation and bonus payments for the CEO and

Managing Director. During the Q4 FY 2021, based on the R&D calculation and cost eligibility assessment for the FY 2021, consulting cost amounting to $332k has been reclassified from R&D to administration and corporate expenses. As always, Prescient continues to prudently manage its cash reserves and operating costs. As the Company continues to progress the development of targeted and cellular cancer therapies, financial management together with its strong cash position will allow the business to pursue multiple value creating milestones.

OmniCAR progress: collaboration; manufacturing and immunogenicity testing

During the quarter Prescient entered an important research partnership with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) to expedite the development of the next generation CAR-T therapy using the OmniCAR platform. The collaboration builds on an earlier agreement between Prescient and Peter Mac announced in August 2020 and will expand collaboration to include OmniCAR. The staff and facilities at Peter Mac are world-class and Prescient's work is being led by international CAR-T expert, Professor Phil Darcy.

Importantly, Prescient will own any resulting intellectual property from the research partnership. Prescient has also secured grant funding of $100,000 from the Australian Federal Government's Innovation Connections scheme towards this important research.

In addition to securing manufacturing and a development partnership with one of the world's leading cancer research institutes, Prescient's team has confirmed other key components of the OmniCAR platform.

Subsequent to the end of the reporting period Precient announced that predicted immunogenicity testing to evaluate the immune response against OmniCAR's components showed favourable responses. The results demonstrated that both SpyTag and SpyCatcher have very low predicted immunogenicity compared to a panel of humanised therapeutic antibodies already approved for human use and predicted immunogenicity on par with human antibodies.

Cell Therapy Enhancement consolidation

Prescient has been undertaking Cell Therapy Enhancement (CTE) programs at both Carina Biotech and Peter Mac. During the period Prescient consolidated these two programs so that they are now being undertaken at Peter Mac, reflecting the growing relationship between

Prescient and Peter Mac. Prescient thanks Carina Biotech and its partners at University of Adelaide for their contribution to the collaboration.

Targeted therapies progress

During the quarter Prescient's targeted therapy studies for PTX-100 and PTX-200 continue to make excellent progress and enrol patients with no safety issues reported by investigators.

On 23 April 2021 Prescient reported on the Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia (AML) has successfully completed the second cohort at 35 mg/m^2 under a modified study protocol, with no safety or toxicity issues observed. The study is now progressing through the higher dose level of 45 mg/m^2 and Prescient looks forward to providing updates in coming months.

Subsequent to the end of the quarter, the Company announced that the Phase 1b basket study of PTX-100 in a mix of solid and haematological cancers has completed recruitment of patients for the highest dose level of 2,000 mg/m^2 with no safety issues reported.

As detailed on 27 July 2021, two patients with T-cell lymphoma remained on the therapy for 12 and 17 months respectively, versus an expected 4 months or less on standard of care therapies. These results have encouraged the Company and Principal Investigator, Professor H. Miles Prince to expand this into a new study of up to 12 patients with this very hard to treat cancer. Prescient looks forward to providing a greater detail around this exciting development in coming months.

The Company thanks all shareholders for their ongoing support and looks forward to updating them as it works to bring effective new personalised cancer treatments to clinicians and their patients who need them.

Investor briefing

Event: Investor Briefing
Date: Friday, 30th July
Time: 11am (AEST)

This is a free event. **Click here to book your spot.**

The Appendix 4C - Quarterly Cash Flow Report for the quarter is attached.

– Ends –

To stay updated with the latest company news and announcements, please update your details on our investor centre: https://prescienttherapeutics.investorportal.com.au/

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.
The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.
OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.
Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).
Cell Therapy Enhancements: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.
PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com, or connect with us via Twitter @PTX_AUS and LinkedIn.

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries:
Warrick Lace – Reach Markets
+61 404 656 408
warrick.lace@reachmarkets.com.au

Media enquiries:
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : Supplemental COVID-19 Risk Factors

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Prescient Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
56 006 569 106	30 June 2021

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(284)	(2,881)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(204)	(690)
	(f) administration and corporate costs	(665)	(1528)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	10	68
1.5	Interest and other costs of finance paid	-	(11)
1.6	Income taxes paid	(5)	-
1.7	Government grants and tax incentives	-	1,081
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,148)**	**(3,961)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(2)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**(2)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	31	13,577
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(837)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**31**	**12,740**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	17,205	7,357
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,148)	(3,961)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(2)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	31	12,740
4.5	Effect of movement in exchange rates on cash held	9	(37)
4.6	**Cash and cash equivalents at end of period**	**16,097**	**16,097**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	6,097	7,205
5.2	Call deposits	10,000	10,000
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**16,097**	**17,205**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	82
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,148)
8.2	Cash and cash equivalents at quarter end (item 4.6)	16,097
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	16,097
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**14.0**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2021

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.